Oncolytics Biotech Inc. (TSX:ONC)
Canada flag Canada · Delayed Price · Currency is CAD
0.5200
-0.0400 (-7.14%)
May 28, 2025, 3:59 PM EDT
-66.01%
Market Cap 46.19M
Revenue (ttm) n/a
Net Income (ttm) -31.50M
Shares Out 88.82M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 188,210
Average Volume 102,587
Open 0.5600
Previous Close 0.5600
Day's Range 0.5200 - 0.5600
52-Week Range 0.5200 - 2.0800
Beta 1.51
RSI 31.55
Earnings Date May 7, 2025

About Oncolytics Biotech

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 28
Stock Exchange Toronto Stock Exchange
Ticker Symbol ONC
Full Company Profile

Financial Performance

Financial Statements

News

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-inf...

5 days ago - PRNewsWire

Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Results Conference Call May 14, 2025 4:30 PM ETCompany ParticipantsJon Patton - Director of Investor Relations...

14 days ago - Seeking Alpha

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic imm...

14 days ago - PRNewsWire

A Look at Oncolytics Biotech's Upcoming Earnings Report

Oncolytics Biotech (NASDAQ: ONCY) is set to give its latest quarterly earnings report on Wednesday, 2025-05-14. Here's what investors need to know before the announcement. Analysts estimate that Onco...

15 days ago - Benzinga

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , May 6, 2025 Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-sta...

22 days ago - PRNewsWire

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest an...

4 weeks ago - PRNewsWire

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered ...

6 weeks ago - PRNewsWire

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

SAN DIEGO and CALGARY, AB , April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discusse...

6 weeks ago - PRNewsWire

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support con...

2 months ago - Benzinga

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support con...

2 months ago - PRNewsWire

Oncolytics Biotech Q4 2024 Earnings Preview

2 months ago - Seeking Alpha

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Feb. 25, 2025 /PRNewswire/ --  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), a l...

3 months ago - PRNewsWire

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential...

3 months ago - PRNewsWire

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor typ...

3 months ago - PRNewsWire

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

SAN DIEGO and CALGARY, AB , Feb. 14, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announc...

3 months ago - PRNewsWire

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Search for Chief Executive Officer to commence immediately SAN DIEGO and CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage comp...

3 months ago - Benzinga

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Search for Chief Executive Officer to commence immediately SAN DIEGO  and  CALGARY, AB , Feb. 7, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage compa...

3 months ago - PRNewsWire

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chem...

4 months ago - Benzinga

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chem...

4 months ago - PRNewsWire

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB , Jan. 15, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), ...

4 months ago - PRNewsWire